CSCIF Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - COSCIENS Biopharma Inc

Watchlist Manager

Watchlist

Price: 2.15 USD 0.94% Market Closed

Market Cap: $6.8m

	COSCIENS Biopharma Inc OTC:CSCIF	CA
R	Reckitt Benckiser Group PLC XETRA:3RB	UK
G	Grammer AG XBER:GMM	DE
	Viel et Compagnie SA PAR:VIL	FR
	Teva Pharmaceutical Industries Ltd OTC:TEVJF	IL
	Maxell Ltd TSE:6810	JP
	Ascendis Pharma A/S NASDAQ:ASND	DK

Profitability Summary

COSCIENS Biopharma Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Healthy Gross Margin

35%

Strong 3Y Average Gross Margin

56%

Declining Gross Margin

97% > 35%

Negative Operating Margin

-138%

Negative 3Y Average Operating Margin

-227%

Operating Margin is Increasing

-265% > -138%

Negative Net Margin

-138%

Negative 3Y Average Net Margin

-211%

Net Margin is Increasing

-259% > -138%

Negative Free Cash Flow Margin

-122%

Negative 3Y Average Free Cash Flow Margin

-197%

Free Cash Flow Margin is Increasing

-180% > -122%

Negative ROE

-122%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-792%

ROIC is Increasing

-345% > -70%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Healthy Gross Margin

35%

Strong 3Y Average Gross Margin

56%

Declining Gross Margin

97% > 35%

Negative Operating Margin

-138%

Negative 3Y Average Operating Margin

-227%

Operating Margin is Increasing

-265% > -138%